In Brief: OncorMed
This article was originally published in The Gray Sheet
Executive Summary
OncorMed: Will begin offering BRCA2 genetic testing Aug. 1 for susceptibility to breast and ovarian cancer, the Gaithersburg, Maryland firm announces. Pricing for BRCA2 testing will be comparable to OncorMed's current BRCA1 gene test: $420 for "stage 1" testing, the portion of the gene most likely to carry a mutation; and $775 for "stage 2" testing. Combined testing for both genes is $500 and $800 for stage 1 and stage 2, respectively. As with BRCA1 testing, BRCA2 testing will be available to physicians and medical centers under protocols developed by in-house institutional review boards or under an OncorMed-developed protocol ("The Gray Sheet" Jan. 15, p. 4)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.